Covid-19 Incidence And Mortality By Age Strata And Comorbidities In Mexico City: A Focus In The Pediatric Population

Nadia González-García; María F Castilla-Peón; Fortino Solórzano Santos; Rodolfo Jiménez Juárez; Maria Elena Martínez Bustamante; Miguel Angel Minero Hibert; Juan Garduño-Espinosa

doi:10.1101/2021.06.21.21259282

Abstract

Background SARS-COV2 appears less frequently and less severely in the pediatric population than in the older age groups. There is a need to precisely estimate the specific risks for each age group to design health and education policies suitable for each population

Objective This study aimed to describe the risk of death in SARS-COV2 infected subjects by age group and according to the presence of comorbidities.

Methods We analyzed data of confirmed SARS-COV2 infection cases where symptoms began between February 22th, 2020, and April 18th, 2021, as published by the General Epidemiology Direction (DGE) of the Mexican Ministry of Health. We calculated COVID-19 incidence and mortality by age group using population data from the Statistics and Population National Institute (INEGI), and estimated the association between risk of death and the presence of comorbidities.

Results Mortality in SARS-COV2 infected people varied considerably, between 7 to 155 deaths per million per year in the under-20 age groups compared to 441 to 15,929 in the older age groups. Mortality in pediatric populations is strongly associated with comorbidities (OR: 4.6-47.9) compared to the milder association for older age groups (OR: 3.16-1.23).

Conclusions The risk of death from SARS-COV2 infection in children is low and is strongly associated with comorbidities.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received for the elaboration o this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Appropriate research reporting guidelines has been folled. This is an analysis of a secondary source, available as open data from de Ministry of Health. So no IRB approval was needed,

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes